Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback